Pembrolizumab,Vibostolimab,Favezelimab
merck
['mibc', 'pembro', 'nmibc']
pembrolizumab could meet unmet need in bcg-unresponsive, high-risk nmibc #medpub #oncotwitter #meded #oncology 
#Oncology news from major publishers consolidated for a more streamlined industry news experience.🎗🗞